Implications of NKG2A in immunity and immune-mediated diseases
Frontiers in Immunology, 2022 In recent studies, NKG2A is revealed to be a key immune checkpoint for both natural killer (NK) cells and CD8+ T cells. It form heterodimer receptors with CD94, and targets the peptide-presenting human leukocyte antigen-E (HLA-E) molecules.
Zhaochen Ning
exaly +5 more sources
Co-editing of NKG2A and FAS increases long-term cytotoxic capacity and persistence of CAR NK cells [PDF]
Molecular Therapy: OncologyNatural killer (NK) cells have the intrinsic ability to kill cancer cells and are thus targeted in immunotherapy. Anti-CD19 CAR NK cells have shown efficacy in clinical studies in treating B cell malignancies; however, the full cytotoxic capacities of ...
Juliane Mietz +11 more
doaj +2 more sources
CD8+ T Cells Form the Predominant Subset of NKG2A+ Cells in Human Lung Cancer
Frontiers in Immunology, 2020 Background: NKG2A is an inhibitory receptor of both T cells and natural killer (NK) cells. Persistent activation promotes T cells and NK cells to express NKG2A and results in the progression of chronic infection and cancer.
Zhongwei Xin, Pin Wu
exaly +3 more sources
Cell Reports, 2021 Summary: Human Vδ2 cells are innate-like γδ T effectors performing potent immune surveillance against tumors. The constitutive expression of NKG2A identifies a subset of Vδ2 T cells licensed with an intrinsic hyper-responsiveness against cancer.
Valentina Cazzetta +2 more
exaly +3 more sources
The inhibitory receptor NKG2A is expressed on T-cells during BKPyVANephropathy [PDF]
Frontiers in ImmunologyIntroductionBKPyV-associated nephropathy (BKPyVAN) is a major complication in kidney transplantation. An exhaustion of BKPyV-specific T-cells but not T-cells against other viruses is observed, suggesting a mechanism specifically mediated by BKPyV ...
Karen Bargiel +18 more
doaj +2 more sources
Nonclassical MHC‐I Molecules: Emerging Therapeutic Targets in Next‐Generation Immunotherapy [PDF]
MedComm (2020)Immunotherapies dependent on classical MHC‐I molecules face significant challenges, including extreme polymorphism and frequent downregulation in pathological conditions. This review discusses how nonclassical MHC‐I molecules (HLA‐E, HLA‐F, HLA‐G, CD1, MR1) may potentially circumvent these limitations through restricted genetic diversity, stable ...
He W, McMichael A.
europepmc +2 more sources
Blocking NKG2A in Echinococcus multilocularis infection partially relieves impairment of NK cell function of the host [PDF]
Cellular and Molecular Life SciencesBackground Alveolar echinococcosis (AE) is a fatal zoonotic parasitic disease with biological characteristics similar to cancer. Although previous studies have reported immune dysfunction of Natural Killer (NK) cells due to other inhibitory receptors in ...
Ayinuer Aierken +8 more
doaj +2 more sources
Improvement of NK Cell Cytotoxicity in Reconstituting NK Cells after Allogeneic Stem Cell Transplantation by Blocking NKG2A Checkpoint [PDF]
Middle East Journal of Cancer, 2023 Background: One cause of tumor relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the alteration of the graft-versus-tumor effect of early reconstituting natural killer (NK) cells due to overexpression of the NKG2A inhibitory
Mohammed Taha, Cyril Fauriat
doaj +1 more source
Hantaan virus-derived peptides that stabilize HLA-E could abrogate inhibition of CD56dimNKG2A+ NK cells. [PDF]
PLoS PathogensNK cells could participate in the pathogenesis process of virus infectious diseases through the inhibitory receptor CD94/NKG2A interacting with HLA-E/virus-derived peptide complex.
Manling Xue +12 more
doaj +2 more sources
KIR+CD8+ and NKG2A+CD8+ T cells are distinct innate-like populations in humans
Cell Reports, 2023 Summary: Subsets of the human CD8+ T cell population express inhibitory NK cell receptors, such as killer immunoglobulin-like receptors (KIRs) and NKG2A.
Seong Jin Choi +7 more
doaj +1 more source